you know, so So the betta cell is tired, it's not working correctly for whatever reason. And then the medication comes along, gives it what what it wants it needs, what it needs stimulates it helps it out. And then it does the thing that it wants to do, right? So if we imagine now what we go V is, and so that's the diabetes medication, right? There's an issue where we, we need to give medicine to fix the issue. And everyone's happy. In a roundabout way, obviously, that's not always what happens. But so now, let's put that trainer that was previously really sweet and nice, and you know, just positive and wonderful. Let's put that trainer on steroids. Let's turn that trainer into Jillian Michaels from The Biggest Loser. And she's mean, and the betta cell that Julian McMichaels, aka semaglutide is training is not in they're not even not even their client. There's a beta cell who's running in the race and is doing really well isn't struggling is happy. They're in the top of the pack. And Jillian McMichaels is like right, I'm going to take it upon myself to go and train that betta cell who I don't like the look of and so Jillian Michaels, runs along to the beta cell, gets out the sports drink and just throws it at the back of her head of the beta cell. And the beta cell is like what the hell and then Julie McMichaels is like drink 10 of those drinks in a row and you've been a guzzle them down and the the betta sellers like, kind of scared and been like, Oh, okay. And then Jillian Michaels that the semaglutide is saying Now kick up your legs and and do some jumping jacks while you're running and do a burpee as well. And so the beater cell finishes the race, but his tie yurts and it's been given all of those those drinks that it was like I'm I mean, I didn't even need anyone on the one of them to throw in the back of my head. And like what the hell that was really, I didn't like that the beta cell could have very comfortably finished that race. But now every race, Julian McMichaels, aka semaglutide is harassing the beta cell, the beta cell will finish the race, but eventually will turn into a genuinely tired beta cell. And then that's when we go back into that original nice trainer that's helping the tired beta cell, because that beta cell is now in the body of someone who has diabetes, because of what Julian McMichael aka semaglutide. The drug that's in we go V has done. Right. So that that's, that's like storytime for you, that is like, you know, very, very rough, very rough idea. And, you know, there's probably lots of holes in that, that very ridiculous example of what that looks like. But you can see why harassing and poking and stimulating these betta cells when there's nothing wrong with them can be problematic. So that is the mechanism of what's happening. And from that, what what happens is, there is appetite suppressants happening in the body and so your brain is like, I'm not that hungry. When you do eat, you're less. You eat, we eat less because you're less hungry. And also the sits the food sits in your digestive system for longer. And there's a lot of problems with that stuff, right? And I'm, you know, I'm telling this stuff and I don't want people to be like, Oh, sounds good. I'm going to go get it. Keep listening to the episode. Okay, so let's look at the science. All right. Now. So we've if we just imagine it, we've got Novo Nordisk at the top as the manufacturer, and then there are two big drugs. The brand name for those diet version of the drugs is saxenda. And we go V. Depending on where you live, you might say we got v. I don't know how you'd say saxenda. differently. Sacks, and I don't know. So they did randomized control trials for both of these drugs. And so we have a lot And I've kind of similar outcomes for both. And so I'm going to give you all of the similar the similar outcomes for both and then and then split it into two and say, What's the difference between success? And and what's, what's different with we go V? Okay. So both? I would say both or because there were there was a few studies in with the published papers, right, the published trials. If you want a good trial paper study about a drug, who would you want to be doing that, you know, drug that can be a drug that has historically been very, very dangerous weight loss drugs in the past have been very dangerous and have been pulled from the market, you would want scientists who have no connection to the drug manufacturers, and who are not influenced by them as much as possible. So some neutral third party, we do not have that here. The trial was planned and funded by novo. And almost every single author has a conflict of interest. They're on the payroll. And so with the SEC sender, all but two, we've been paid by we go V and on by novo, and with the weego V, every single author was on the payroll of Novo. So you can see that that is a conflict of interest there, you're being paid by this company, might you be a little bit influenced by that. And so,